Navigation Links
Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
Date:6/2/2008

DecisionLine adds high-end exploratory/translational medicine capabilities and world-leading scientific psychopharmacology expertise; supports Kendle

strategic initiative to drive growth in its early phase business

CINCINNATI, June 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading global full-service clinical research organization (CRO), today announced the acquisition of DecisionLine Clinical Research Corporation (DecisionLine Clinical Services), a privately owned, early phase CRO with a state-of-the-art medical facility in Toronto, Canada. DecisionLine specializes in the conduct of Phase I studies involving the measurement of pharmacodynamic effects of central nervous system (CNS) drugs, and is recognized worldwide as a leader in the conduct of human abuse liability studies and the assessment of abuse potential and risk mitigation. The company brings to Kendle extensive world-class scientific expertise with psychopharmacology high-end exploratory/translational medicine capabilities, from first-in-human to proof-of-concept trial conduct, as well as drug development consulting, medical writing, data management, biostatistics and other support services. Kendle acquired DecisionLine for an undisclosed cash amount. Specific terms of the transaction were not disclosed. The acquired business will report into Philip J.W. Davies, Vice President, Early Phase.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

"With Phase I growth expected to outpace the broader outsourcing market at approximately 15 percent annually, early phase development remains an important need for our customers and an area of significant growth opportunity for Kendle," said President Simon Higginbotham. "The addition of DecisionLine is an important step in building Kendle's global capabilities for exploration of early phase drug candidates and supports our strategic initiative to drive growth in our Phase I business. We look forward to leveraging the benefits of our combined and strengthened scientific expertise as we assist our customers in tapping their most promising new compounds for development."

DecisionLine was founded in 1997 by President and CEO Edward M. Sellers, MD, PhD, FRCPC, FACP and Senior Vice President, Research Development & Medical Affairs Myroslava K. Romach, MSc, MD, FRCPC. The company's 82-bed, 36,000-square foot medical facility is staffed by a team of internationally recognized scientists, including clinical pharmacologists and neuropsychologists, physicians, research nurses, pharmacists, paramedics and research assistants. DecisionLine employs approximately 110 full-time and 130 part-time associates. The company has grown its revenue at an average compound annual growth rate of 60 percent since 2002, and has been named to Profit magazine's list of the top 100 fastest growing companies in Canada. Dr. Sellers and Dr. Romach will play key leadership roles as part of Kendle's Early Phase organization. Dr. Sellers will serve as General Manager, Early Phase, Toronto and Senior Scientist, Kendle International and Dr. Romach will assume the role of Head of Clinical Operations and Medical Affairs, Early Phase, Toronto and Senior Scientist, Kendle International.

"We are extremely pleased to join Kendle," said Dr. Sellers, "DecisionLine's specialized experience in Phase I together with Kendle's global capabilities and footprint will provide great benefits to the customers, investors and associates of our combined organization as we work to establish Kendle as a world leader in early phase development services."

Kendle's existing early phase capabilities include a Clinical Pharmacology Unit (CPU) in Utrecht, The Netherlands, and a Bioequivalence Unit in Morgantown, W.Va. Kendle's CPU is strategically located on the campus of University Hospital Utrecht and includes a 48-bed facility plus visit area with on-site project management, recruitment and screening, sample handling, pharmacy (GMP), quality control, clinical data management, biostatistics, medical writing, a Phase IIA team and independent Clinical Quality Assurance. The company's bioequivalence facility, located near West Virginia University, has been in operation for more than 25 years and provides bed space for 118 subjects.

Investor Webcast and Conference Call

Kendle will host a telephone conference call and Webcast Tuesday, June 3 at 9:30 a.m. Eastern Time to discuss the DecisionLine acquisition and provide an update on second quarter progress.

Conference Call Details

Dial in: 800-399-0069 (United States and Canada)

706-643-3694 (Outside North America)

Replay: 706-645-9291

Conference ID Number 50042856

Webcast

Please go to http://www.kendle.com or

http://www.videonewswire.com/event.asp?id=48934. The Webcast will be

archived at http://www.kendle.com (click on "Investors") shortly after the call.

The conference call and archived Webcast will be available until 5 p.m.

Eastern Time on July 3.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com .

Information provided herein, which is not historical information, such as statements about prospective earnings, revenue and earnings growth, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements, including the statements contained herein regarding anticipated trends in the company's business, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors and industry consolidation, outsourcing trends in the pharmaceutical and biotechnology industries, the company's ability to manage growth and to continue to attract and retain qualified personnel, the company's ability to complete additional acquisitions and to integrate newly acquired businesses, the company's ability to penetrate new markets, the fixed price nature of contracts and cost overruns, the loss, cancellation or delay of contracts or amendments thereto, the ability to maintain existing customer relationships or enter into new ones, the company's sales cycle, the effects of exchange rate fluctuations, risks related to non-U.S. operations and other factors described in the company's filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K. No assurance can be given that the company will be able to realize the net service revenues included in backlog and verbal awards. Kendle believes that its aggregate backlog and verbal awards are not necessarily a meaningful indicator of future results. All information in this release is current as of June 2, 2008. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):